Cardio.AI®

XOresearch is a Latvia-based startup that has been operating since 2015. The company has developed a groundbreaking product named CardioAI, an AI-powered platform for high accuracy automatic annotation and interpretation of long and short ECG records. This proprietary software medical device utilizes deep learning technology to rapidly and accurately process ECG data, reducing the processing time for a single 24-hour ECG to about 30 seconds. This feature enables real-time monitoring and analysis of patients with heart conditions, offering physicians and caregivers an efficient tool to manage chronic conditions and potentially reduce non-essential hospitalizations. CardioAI is a feature-rich productivity tool designed to accelerate the interpretation of electrocardiograms, especially beneficial for prolonged or constant cardiac monitoring. It allows for better health surveillance in remote, difficult, or dangerous locations, providing accurate near real-time processing for unprecedented medical support. The software can be seamlessly integrated into an EHR system or incorporated into a mobile health device, making it adaptable to various business requirements. Notably, XOresearch takes data privacy seriously and their API does not accept any personal data with the signal, with reports modified on the client's side to add sensitive information. XOresearch operates at the intersection of healthcare and information technology industries, addressing a critical need for efficient cardiac monitoring and analysis. Although there is no available information about their latest investment or investors, the innovative nature of CardioAI and its potential to revolutionize cardiac care make XOresearch an intriguing prospect for venture capital firms seeking investment opportunities in the healthcare technology sector.